COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
申请人:Genentech, Inc.
公开号:US20170157124A1
公开(公告)日:2017-06-08
The invention provides combinations comprising a) compound of formula I:
or a pharmaceutically acceptable salt thereof wherein R
1
, R
2
, R
5
, R
10
, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.